A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

A Non-interventional and Retrospective Study Describing the Patient Profile and Treatment Patterns in Real-world Melanoma Patients Prescribed With Dab+Tram or Enco+Bini in Japan

The aim of this study was to describe the patient profile and treatment patterns of adult melanoma patients that were treated with either dabrafenib and trametinib (Dab+Tram) or encorafenib and binimetinib (Enco+Bini) between 01 January 2012 and 30 November 2021 in Japan.

Inclusion criteria:

All patients who met all of the following criteria were included:

• Had a confirmed diagnosis of melanoma recorded during the identification period, and
• Had at least 6 months of enrollment before the index date A, where index date A was defined as the first date of a confirmed diagnosis of melanoma recorded during the identification period, and
• Were at least 18 years old at the time of initiation of the first line of treatment (LoT).

The Adjuvant Dab+Tram Cohort included all patients who met all of the following criteria:

• Satisfied all of the general inclusion criteria, and
• Had a dabrafenib prescription claim and a trametinib prescription claim recorded after or at the index date A, and
• Had at least 6 months of follow-up after the index date B, where index B was defined as the first date of a prescription recorded at or after index date A, and
• Had the first dabrafenib or trametinib prescription claim recorded within 12 weeks of an excision surgery, and
• Did not have a confirmed metastasis diagnosis recorded within 1 month before, at, or within 12 weeks after the index date A.

The Non-adjuvant Dab+Tram Cohort included all patients that met all of the following criteria:

• Satisfied all of the general inclusion criteria, and
• Had a dabrafenib prescription claim and a trametinib prescription claim recorded after or at the index date A, and
• Had at least 6 months of follow-up after the index date B, and
• Not included in the Adjuvant Dab+Tram Cohort.

The Cohort Enco+Bini included all patients that met all of the following criteria:

• Satisfied all of the general inclusion criteria, and
• Had an encorafenib prescription claim and a binimetinib prescription claim recorded after or at the index date A, and
• Had at least 6 months of follow-up after the index date B.

The Overall Cohort included all patients that met all of the following criteria:

• Included in either the Adjuvant Dab+Tram Cohort, the Non-adjuvant Dab+Tram Cohort, or the Enco+Bini Cohort. A patient could be considered in multiple cohorts and was considered once only in analysis of the Overall Cohort.

Exclusion criteria:

• Had a prescription claim with a melanoma treatment recorded within 6 months before the index date A, or
• Had a confirmed diagnosis of a non-small cell lung cancer recorded any time before the index date A for the Adjuvant Dab+Tram Cohort and the Non-adjuvant Dab+Tram Cohort, or
• Had a confirmed diagnosis of a colorectal cancer recorded any time before the index date A for the Enco+Bini Cohort.